ReviewTrends in cancer2018
Glypicans as Cancer Therapeutic Targets.
Review in Trends in cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 1 synthesis or guideline pooled it, 153 citations in OpenAlex.
- Dynamic Remodeling of Oocyte-Granulosa Cell Communication During Bovine Folliculogenesis Revealed by Transcriptomic Meta-Analyses.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Pooled it
- Genome-Wide Differentiation, Inbreeding, and Candidate Selection Loci in Local Vietnamese Pig Breeds.International journal of molecular sciences · 2026Article
- Glypican-3-targeted therapy in hepatocellular carcinoma: biological insights and therapeutic strategies.Cancer gene therapy · 2026Review
- Proteoglycans as Molecular Regulators of Bone Metastasis: Extracellular Matrix Remodeling, Tumor-Bone Crosstalk, Dormancy, and Therapeutic Opportunities.Biomolecules · 2026Review
- Paediatric therapeutic development workshop on medulloblastoma.British journal of cancer · 2026Review
- Allogeneic CRISPR-Engineered CAR-T Cells Drive Potent Antitumor Activity in Solid Tumors.bioRxiv : the preprint server for biology · 2026Article
- Article
- Review
- Identification and Nonclinical Characterization of SAR444200, a Novel Anti-GPC3 NANOBODY T-cell Engager, for the Treatment of GPC3+ Solid Tumors.Molecular cancer therapeutics · 2026Article
- Explainable machine learning-based multiphase contrast-enhanced CT radiomics for noninvasively predicting GPC3 expression in hepatocellular carcinoma: a bicentric study.American journal of translational research · 2026Article
- Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential.Communications biology · 2025Article
- Proteoglycans in Breast Cancer: Friends and Foes.Biomolecules · 2025Review
- Antibody-gamma/delta T cell receptors targeting GPC2 regress neuroblastoma with low antigen density.Cell reports. Medicine · 2025Article
- Targeting glypican-3 as a new frontier in liver cancer therapy.World journal of hepatology · 2025Review
- Proteomics in pancreatic cancer.Biomarker research · 2025Review
- Changes in Gene Expression Patterns in Young and Senescent Fibroblasts in Glycated Three-Dimensional Collagen Matrices.International journal of molecular sciences · 2025Article
- A model of basement membrane-related regulators for prediction of prognoses in esophageal cancer and verification in vitro.BMC cancer · 2025Article
- Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and Challenges.The American journal of pathology · 2025Review
- Diagnostic value of glypican-1; a new marker differentiating pulmonary squamous cell carcinoma from adenocarcinoma: immunohistochemical study on Egyptian series.Clinical and experimental medicine · 2025Article
- Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Glypicans are a group of cell-surface glycoproteins in which heparan sulfate (HS) glycosaminoglycan chains are covalently linked to a protein core. The glypican gene family is broadly conserved across animal species and plays important roles in biological processes. Glypicans can function as coreceptors for multiple signaling molecules known for regulating cell growth, motility, and differentiation. Some members of the glypican family, including glypican 2 (GPC2) and glypican 3 (GPC3), are expressed in childhood cancers and liver cancers, respectively. Antibody-based therapies targeting glypicans are being investigated in preclinical and clinical studies, with the goal of treating solid tumors that do not respond to standard therapies. These studies may establish glypicans as a new class of therapeutic targets for treating cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.